In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Jonathan Ledermann to discuss ICON8-Overall Survival. Jonathan Ledermann is a professor of medical oncology and Clinical Director at UCL Cancer Institute specializing in the treatment and research of gynaecological malignancies. He has led several national and international trials on the treatment of ovarian cancer and has played a key role in developing trials of PARP inhibitors in ovarian cancer. He is the ESMO Gynaecological Cancer Practice Guidelines Editor and past Vice President of ESGO. He is a Fellow of the Academy of Medical Sciences and a Senior Investigator for the National Institute of Health Research in the UK.

Highlights:

- Weekly first-line chemotherapy for ovarian cancer does not improve progression-free or overall survival.

- ICON8 was the largest randomized trial exploring weekly paclitaxel or weekly carboplatin and paclitaxel compared to tri-weekly chemotherapy.

- There is no evidence to suggest that weekly first-line chemotherapy should be used as part of multimodal treatment of newly diagnosed ovarian cancer.

- The results in a predominately European population differ from a similar Japanese trial, raising the possibility that genetic or pharmacogenomic differences need to be considered when comparing the results of trials in ovarian cancer.